Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Pro

Showing results (131-140 of 187) with videos related to

Pageof 19
Sort By:
Cancer|January 28, 2003
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera, L Jeffrey Medeiros, Frederick B Hagemeister, et al.
Blood|January 27, 2009
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphomaConstantine S Tam, Roland Bassett, Celina Ledesma, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.
Leukemia & Lymphoma|March 26, 2015
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trialMeghan Karuturi, Anas Younes, Luis Fayad, et al.
Blood|September 29, 2020
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphomaPamela B Allen, Hatice Savas, Andrew M Evens, et al.
JAMA Oncology|March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical TrialLocke J Bryan, Carla Casulo, Pamela B Allen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 28, 2014
A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage diseaseDolores Grosso, Sameh Gaballa, Onder Alpdogan, et al.
British Journal of Haematology|December 3, 2015
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trialRanjana H Advani, Stephen M Ansell, Mary J Lechowicz, et al.
Haematologica|January 29, 2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experiencePaolo Anderlini, Rima Saliba, Sandra Acholonu, et al.
Pageof 19

Showing results (131-140 of 187) with videos related to

Sort By:
Pageof 19
Cancer|January 28, 2003
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera, L Jeffrey Medeiros, Frederick B Hagemeister, et al.
Blood|January 27, 2009
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphomaConstantine S Tam, Roland Bassett, Celina Ledesma, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.
Leukemia & Lymphoma|March 26, 2015
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trialMeghan Karuturi, Anas Younes, Luis Fayad, et al.
Blood|September 29, 2020
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphomaPamela B Allen, Hatice Savas, Andrew M Evens, et al.
JAMA Oncology|March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical TrialLocke J Bryan, Carla Casulo, Pamela B Allen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 28, 2014
A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage diseaseDolores Grosso, Sameh Gaballa, Onder Alpdogan, et al.
British Journal of Haematology|December 3, 2015
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trialRanjana H Advani, Stephen M Ansell, Mary J Lechowicz, et al.
Haematologica|January 29, 2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experiencePaolo Anderlini, Rima Saliba, Sandra Acholonu, et al.
Pageof 19